Literature DB >> 2344857

Digoxin infusion versus bolus injection in rapid atrial fibrillation: relation between serum level and response.

A J Smit1, A H Scaf, L H van Essen, K I Lie, H Wesseling.   

Abstract

Using available data on time-concentration and time-effect relationships in normal persons the results of infusion of digoxin in various time periods were simulated and compared with administration of digoxin by bolus injections, using a three-compartment pharmacokinetic model to which a separate small side-effect compartment was subsequently added. The validity of the simulations was tested in 11 patients with rapid atrial fibrillation. Serum digoxin concentrations, ventricular rate and side effects were monitored in a double-blind study comparing an infusion of 1.5 mg digoxin over 6 h with administration of three bolus injections of 0.5 mg digoxin 8 h apart. In agreement with the predictions of the model, the maximal fall in ventricular rate was reached after 8-9 h in the infusion group and after 19-20 h in the bolus injection group, without any detectable difference in side effects. There were certain discrepancies between the results of the clinical study and the predictions of the model, e.g. in serum digoxin concentrations, perhaps due to impaired clearance in the patients. However, it is concluded that the tested model is valid in elderly patients with rapid atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344857     DOI: 10.1007/bf00315571

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man.

Authors:  W G Kramer; A J Kolibash; R P Lewis; M S Bathala; J A Visconti; R H Reuning
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

2.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

3.  Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man.

Authors:  W G Kramer; R P Lewis; T C Cobb; W F Forester; J A Visconti; L A Wanke; H G Boxenbaum; R H Reuning
Journal:  J Pharmacokinet Biopharm       Date:  1974-08

4.  Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin.

Authors:  R H Reuning; R A Sams; R E Notari
Journal:  J Clin Pharmacol New Drugs       Date:  1973-04

5.  [Ophthalmological aspects of digitoxin poisoning].

Authors:  M Cozijnsen; A J Pinckers
Journal:  Ned Tijdschr Geneeskd       Date:  1969-10-04

6.  Pharmacokinetic analyses with RUGFIT: an interactive pharmacokinetic computer program.

Authors:  A H Scaf
Journal:  Biopharm Drug Dispos       Date:  1988 Sep-Oct       Impact factor: 1.627

7.  Rapid achievement of a serum concentration plateau of digoxin through controlled infusion.

Authors:  M Weiss; W Sziegoleit; A Fahr; W Förster
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients.

Authors:  Y J Sohn; A F Bencini; A H Scaf; U W Kersten; S Agoston
Journal:  Anesth Analg       Date:  1986-03       Impact factor: 5.108

9.  Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications.

Authors:  D J Sumner; A J Russell
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

10.  Clinical course of acute atrial fibrillation treated with rapid digitalization.

Authors:  P Weiner; M M Bassan; J Jarchovsky; S Iusim; L Plavnick
Journal:  Am Heart J       Date:  1983-02       Impact factor: 4.749

  10 in total
  1 in total

1.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.